No Data
No Data
Anavex Reports Phase III Results for Alzheimer's Drug Targeting SIGMAR1 Gene
Anavex Life Sciences Shares Are Trading Higher After the Company Announced New Data From the Phase IIb/III Study Showing That Blarcamesine, Once Daily Orally, Demonstrates Pre-specified Clinical Efficacy Through Upstream SIGMAR1 Activation.
12 Health Care Stocks Moving In Thursday's Intraday Session
JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15
Anavex Life Sciences Is Maintained at Buy by EF Hutton
Anavex Gains as Lead Asset Slows Alzheimer's Disease Progression by a Third
No Data
No Data
Rockhoundj : $Cardio Diagnostics (CDIO.US)$
Is looking strong
Take a
Stock_Drift OP Rockhoundj : Agreed. Could be a good AH’s run!!?
Stock_Drift OP Rockhoundj : Let’s Go!!! $Cardio Diagnostics (CDIO.US)$